Search - tctmd.com

Displaying 1 - 20 of 28

Sort: Relevancy | Date

Presentation TVT 2022

Durability Matters: Results of the High Risk-SURTAVI 5 year outcomes.

Presenter: Joshua Rovin

June 09, 2022

Presentation ACC 2022

5-Year Incidence, Outcomes and Predictors of Structural Valve Deterioration of Transcatheter and Surgical Aortic Bioprostheses: Insights from the CoreValve US Pivotal and SURTAVI Trials

Presenter: Michael J. Reardon

April 04, 2022

Presentation TCT 2021

SURTAVI: Five-Year Results From a Randomized Trial of TAVR vs. SAVR in Patients at Intermediate Surgical Risk

Presenter: Nicolas Van Mieghem

November 05, 2021

Presentation TCT 2020

TCT 125: TAVR with a Supra-Annular, Self-Expandable Valve in Intermediate Risk Patients: Follow-Up From the SURTAVI Randomized Trial and Continued Access Registry

Presenter: Paul Mahoney

October 14, 2020

Presentation TVT 2019

Functional Status After Transcatheter and Surgical Aortic Valve Replacement: A Two-Year Analysis From the SURTAVI Trial

Presenter: Mark Tuttle

June 15, 2019

Presentation TVT 2019

Functional Status After Transcatheter and Surgical Aortic Valve Replacement: A 2-Year Analysis From the SURTAVI Trial

Presenter: Mark Tuttle

June 13, 2019

Presentation TCT 2018

SURTAVI: Two-Year Complete Results From a Randomized Trial of a Self-Expanding Transcatheter Heart Valve vs Surgical Aortic Valve Replacement in Patients With Severe Aortic Stenosis at Intermediate Surgical Risk

Presenter: Horst Sievert, Brian K. Whisenant, Jeffrey J. Popma

September 23, 2018

Presentation TCT 2017

SURTAVI Trial Critique and Unanswered Questions

Presenter: David J. Moliterno, Vinod H. Thourani, E. Murat Tuzcu

November 01, 2017

Presentation TCT 2017

SURTAVI: Topline Findings and Practice Implications

Presenter: David J. Moliterno, Vinod H. Thourani, Nicolas M. Van Mieghem

November 01, 2017

Presentation TCT 2017

TCT 107: Transcatheter Aortic Valve Replacement With a Self-Expanding Prosthesis or Surgical Aortic Valve Replacement in Intermediate-Risk Patients: Complete 1-Year Outcomes From the SURTAVI Trial

Presenter: Steven R. Bailey, Patrick W. Serruys, Nicolas M. Van Mieghem

November 01, 2017

Presentation TCT 2017

TCT 39: Clinical Outcomes in SURTAVI Based on Revascularization Stratification

Presenter: Jean-Claude Laborde, Eric Van Belle, Lars Sondergaard

October 31, 2017

Presentation TCT 2017

Viewpoint #1: PARTNER 2A and SURTAVI are Convincing TAVR is Preferred in ALL (Appropriate) Intermediate-Risk Patients

Presenter: Michael J. Reardon

October 30, 2017

Presentation TCT 2017

Featured Lecture: Transcatheter Aortic Valve Replacement With a Self-Expanding Prosthesis or Surgical Aortic Valve Replacement in Intermediate-Risk Patients : Complete 1-Year Outcomes from the SURTAVI Trial

Presenter: Martin B. Leon, Patrick T. O'Gara, Nicolas M. Van Mieghem

October 30, 2017

Presentation TVT 2017

After PARTNER 2A/S3i and SURTAVI, What Is the Role of Surgery in Intermediate-Risk AS Patients?

Presenter: David J. Cohen, Jeffrey J. Popma, Vinod H. Thourani

June 16, 2017

Presentation TVT 2017

SURTAVI Vignette III: Subset Analysis of Strokes

Presenter: David J. Cohen, Jeffrey J. Popma, A. Pieter Kappetein

June 16, 2017

Presentation TVT 2017

SURTAVI Vignette II: Subset Analysis of Patients With STS < 3% (Lower-Risk Patients)

Presenter: David J. Cohen, Jeffrey J. Popma

June 16, 2017

Presentation TVT 2017

SURTAVI Vignette I: Applying Bayesian Methodology to Interventional Clinical Trials

Presenter: David J. Cohen, Jeffrey J. Popma

June 16, 2017

Presentation TVT 2017

Spotlight Lecture: The SURTAVI LBCT: CoreValve vs Surgery in Intermediate-Risk Aortic Stenosis Patients

Presenter: David J. Cohen, Jeffrey J. Popma, Michael J. Reardon

June 16, 2017

Transcatheter Aortic Valve Replacement with a Self-Expanding Prosthesis or Surgical Aortic Valve Replacement in Intermediate-Risk Patients: First Results from the SURTAVI Clinical Trial

Presentation ACC 2017

First Results from the SURTAVI Clinical Trial

Presenter: Michael J. Reardon

March 17, 2017

Presentation TCT 2016

Intermediate-Risk Studies II: Updates From SURTAVI

Presenter: Patrick T. O'Gara, Alec S. Vahanian, Jeffrey J. Popma

October 30, 2016

Advertisement

Durability Matters: Results of the High Risk-SURTAVI 5 year outcomes.

5-Year Incidence, Outcomes and Predictors of Structural Valve Deterioration of Transcatheter and Surgical Aortic Bioprostheses: Insights from the CoreValve US Pivotal and SURTAVI Trials

SURTAVI: Five-Year Results From a Randomized Trial of TAVR vs. SAVR in Patients at Intermediate Surgical Risk

TCT 125: TAVR with a Supra-Annular, Self-Expandable Valve in Intermediate Risk Patients: Follow-Up From the SURTAVI Randomized Trial and Continued Access Registry

Functional Status After Transcatheter and Surgical Aortic Valve Replacement: A Two-Year Analysis From the SURTAVI Trial

Functional Status After Transcatheter and Surgical Aortic Valve Replacement: A 2-Year Analysis From the SURTAVI Trial

SURTAVI: Two-Year Complete Results From a Randomized Trial of a Self-Expanding Transcatheter Heart Valve vs Surgical Aortic Valve Replacement in Patients With Severe Aortic Stenosis at Intermediate Surgical Risk

SURTAVI Trial Critique and Unanswered Questions

SURTAVI: Topline Findings and Practice Implications

TCT 107: Transcatheter Aortic Valve Replacement With a Self-Expanding Prosthesis or Surgical Aortic Valve Replacement in Intermediate-Risk Patients: Complete 1-Year Outcomes From the SURTAVI Trial

TCT 39: Clinical Outcomes in SURTAVI Based on Revascularization Stratification

Viewpoint #1: PARTNER 2A and SURTAVI are Convincing TAVR is Preferred in ALL (Appropriate) Intermediate-Risk Patients

Featured Lecture: Transcatheter Aortic Valve Replacement With a Self-Expanding Prosthesis or Surgical Aortic Valve Replacement in Intermediate-Risk Patients : Complete 1-Year Outcomes from the SURTAVI Trial

After PARTNER 2A/S3i and SURTAVI, What Is the Role of Surgery in Intermediate-Risk AS Patients?

SURTAVI Vignette III: Subset Analysis of Strokes

SURTAVI Vignette II: Subset Analysis of Patients With STS < 3% (Lower-Risk Patients)

SURTAVI Vignette I: Applying Bayesian Methodology to Interventional Clinical Trials

Spotlight Lecture: The SURTAVI LBCT: CoreValve vs Surgery in Intermediate-Risk Aortic Stenosis Patients

First Results from the SURTAVI Clinical Trial

Intermediate-Risk Studies II: Updates From SURTAVI

Advertisement

Advertisement

Sign In

Forgot Your Password?

Search TCTMD

CME TITLE

Sign up for our newsletter

Search TCTMD

Submit an Event

Become a PREMIUM MEMBER or LOG IN to view exclusive content

REGISTER for free or LOG IN to view this content